Search

everythinglearnresearchcommunity

for

Search:↓

Research 10 of 289

1. CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane‐induced alopecia EMBO Molecular Medicine · 2019 · 58 citations
2. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients Supportive Care in Cancer · 2023 · 9 citations
3. CDK4/6 plus aromatase inhibitor-induced alopecia in breast cancer patients. Journal of Clinical Oncology · 2019 · 4 citations
4. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm Asia-Pacific Journal of Clinical Oncology · 2018 · 4 citations
5. Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis Journal of Managed Care & Specialty Pharmacy · 2025 · 1 citations
6. Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China BMC Cancer · 2025 · 1 citations
7. Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study. Journal of Clinical Oncology · 2024
8. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer. Journal of Clinical Oncology · 2023
9. Alopecia induced by CDK 4/6 Inhibitors and its Impact on the Quality of Life of Patients with advanced Breast cancer 2025
10. Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment Patient Preference and Adherence · 2021 · 12 citations

Community

— no results